Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Self-care in Europe

This article was originally published in The Tan Sheet

Executive Summary

Self-managing health care is becoming increasingly acceptable in Europe, Hubertus Cranz, PhD, director general of the Association of the European Self-Medication Industry (AESGP) said during CHPA's Regulatory & Scientific Conference in Washington, D.C. May 2. "Ten, 15 years ago it would have been impossible to even talk about a patient self-managing health care," he explained, describing the European setting as "much more restrictive" than that in the U.S. or UK. Progress has since been made, Cranz said, pointing out that from 2001 to 2002 the Standing Committee of European Doctors participated in AESGP's study on new indications for self-medication. In 2006, the AESGP was involved in a joint project with the World Medical Association entitled, "From Patient to Self-Health Manager." Cranz credited the UK for setting the example, explaining that the "UK government policy is to encourage self-care"...

You may also be interested in...

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts